id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-322641-mz0b91xr	Farnsworth, Christopher W	SARS-CoV-2 Serology: Much Hype, Little Data	2020-04-28		.txt	text/plain	1566	96	48	In response to a lack of COVID-19 testing the FDA issued guidance regarding serologic assays, stating that although manufacturers could use the Emergency Use Authorization (EUA) pathway for approval, serologic assays could also be marketed in the US bypassing this approval process (2) . Serology has been suggested to play three roles in the COVID-19 pandemic; 1) diagnosis, 2) identification of convalescent plasma donors, 3) screening populations with the purpose of determining exposure and immunity. If the prevalence of COVID-19 in the population is 20% a test with a sensitivity and specificity of 98% will make the value of a positive result (PPV) 92.5% (Figure 1 ). The importance of specificity of serologic tests for screening low prevalence populations was recently demonstrated in a non-peer reviewed publication (11) . The authors found that 1.5% of those screened were positive for SARS-CoV-2 antibodies and, after analysis, found the estimated prevalence to be 2.4%.	./cache/cord-322641-mz0b91xr.txt	./txt/cord-322641-mz0b91xr.txt